Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Pharmacogenomics and Laboratory Medicine
137
Lindor, N.M., McMaster, M.L., Lindor, C.J., Greene, M.H., National Cancer Institute, Division
of Cancer Prevention, Community Oncology, and Prevention Trials Research Group.
(2008). Concise handbook of familial cancer susceptibility syndromes—Second edition.
Journal of the National Cancer Institute Monographs 38, 1–93.
Lipton, L., and Tomlinson, I. (2006). The genetics of FAP and FAP-like syndromes. Familial
Cancer 5, 221–226.
Lynch, H.T., Shaw, M.W., Magnuson, C.W., Larsen, A.L., and Krush, A.J. (1966). Hereditary
factors in cancer. Study of two large midwestern kindreds. Archives of Internal
Medicine 117, 206–212.
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W.,
Harris, P.L., et al. (2004). Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England
Journal of Medicine 350, 2129–2139.
Mackenzie, P.I., Bock, K.W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J.O.,
Owens, I.S., and Nebert, D.W. (2005). Nomenclature update for the mammalian UDP
glycosyltransferase (UGT) gene superfamily. Pharmacogenetics and Genomics 15,
677–685.
Martelli, M.P., Sozzi, G., Hernandez, L., Pettirossi, V., Navarro, A., Conte, D., Gasparini, P.,
et al. (2009). EML4-ALK rearrangement in non-small cell lung cancer and non-tumor
lung tissues. The American Journal of Pathology 174, 661–670.
Martis, S., Peter, I., Hulot, J.S., Kornreich, R., Desnick, R.J., and Scott, S.A. (2013). Multiethnic
distribution of clinically relevant CYP2C genotypes and haplotypes. The
Pharmacogenomics Journal 13, 369–377.
McGraw, J., and Waller, D. (2012). Cytochrome P450 variations in different ethnic populations.
Expert Opinion on Drug Metabolism & Toxicology 8, 371–382.
McLeod, H.L., Krynetski, E.Y., Relling, M.V., and Evans, W.E. (2000). Genetic polymorphism
of thiopurine methyltransferase and its clinical relevance for childhood acute
lymphoblastic leukemia. Leukemia 14, 567–572.
Meindl, A., Ditsch, N., Kast, K., Rhiem, K., and Schmutzler, R.K. (2011). Hereditary breast
and ovarian cancer: New genes, new treatments, new concepts. Deutsches Arzteblatt
International 108, 323–330.
Narita, I., Goto, S., Saito, N., Song, J., Omori, K., Kondo, D., Sakatsume, M., and Gejyo, F.
(2003). Angiotensinogen gene variation and renoprotective efficacy of renin–angiotensin
system blockade in IgA nephropathy. Kidney International 64, 1050–1058.
NCI (National Cancer Institute). (2015). Cancer Stat Fact Sheets. http://seercancergov/
Nevanlinna, H., and Bartek, J. (2006). The CHEK2 gene and inherited breast cancer susceptibility.
Oncogene 25, 5912–5919.
Nowell, P.C., and Hungerford, D.A. (1960). A minute chromosome in human chronic granulocytic
leukemia. Science 132, 1497–1501.
Olivier, M., Goldgar, D.E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P., and Eeles, R.A.
(2003). Li-Fraumeni and related syndromes: Correlation between tumor type, family
structure, and TP53 genotype. Cancer Research 63, 6643–6650.
Owens, M.A., Horten, B.C., and Da Silva, M.M. (2004). HER2 amplification ratios by fluorescence
in situ hybridization and correlation with immunohistochemistry in a cohort
of 6556 breast cancer tissues. Clinical Breast Cancer 5, 63–69.
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., et al. (2004).
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.
Science 304, 1497–1500.
Pakakasama, S., Kajanachumpol, S., Kanjanapongkul, S., Sirachainan, N., Meekaewkunchorn, A.,
Ningsanond, V., and Hongeng, S. (2008). Simple multiplex RT-PCR for identifying common
fusion transcripts in childhood acute leukemia. International Journal of Laboratory
Hematology 30, 286–291.